Tafenoquine at therapeutic concentrations does not prolong fridericia‐corrected QT interval in healthy subjects. (9th April 2014)

• Record Type: Journal Article
• Authors: Green, Justin A.; Patel, Apurva K.; Patel, Bela R.; Hussaini, Azra; Harrell, Emma J.; McDonald, Mirna J.; Carter, Nick; Mohamed, Khadeeja; Duparc, Stephan; Miller, Ann K.
• Is Part Of: Journal of clinical pharmacology. Volume 54:Number 9(2014:Sep.)
• Page Start: 995
• Page End: 1005
• Publication Date: 2014-04-09
• Subjects: Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.302
• Languages: English
• ISSNs: 0091-2700

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="jcph302-sec-0001" sec-type="section"> <p>Tafenoquine is being developed for relapse prevention in <italic>Plasmodium vivax</italic> malaria. This Phase I, single‐blind, randomized, placebo‐ and active‐controlled parallel group study investigated whether tafenoquine at supratherapeutic and therapeutic concentrations prolonged cardiac repolarization in healthy volunteers. Subjects aged 18–65 years were randomized to one of five treatment groups (n = 52 per group) to receive placebo, tafenoquine 300, 600, or 1200 mg, or moxifloxacin 400 mg (positive control). Lack of effect was demonstrated if the upper 90% CI of the change from baseline in QTcF following supratherapeutic tafenoquine 1200 mg versus placebo (ΔΔQTcF) was <10 milliseconds for all pre‐defined time points. The maximum ΔΔQTcF with tafenoquine 1200 mg (n = 50) was 6.39 milliseconds (90% CI 2.85, 9.94) at 72 hours post‐final dose; that is, lack of effect for prolongation of cardiac depolarization was demonstrated. Tafenoquine 300 mg (n = 48) or 600 mg (n = 52) had no effect on ΔΔQTcF. Pharmacokinetic/pharmacodynamic modeling of the tafenoquine–QTcF concentration–effect relationship demonstrated a shallow slope (0.5 ms/μg mL<sup>–1</sup>) over a wide concentration range. For moxifloxacin (n = 51), maximum ΔΔQTcF was 8.52 milliseconds (90% CI 5.00, 12.04), demonstrating assay sensitivity. In this thorough QT/QTc study, tafenoquine did not have a clinically meaningful effect on cardiac repolarization.</p> </sec> </abstract>